144 ·Filed Jun 5, 2026

ANAB

ANAPTYSBIO, INC
BEARISH
Impact 5/10
Horizondays Processed3mo ago SEC0001950047-26-005679
Form 144 — notice of proposed sale of securities
Actionable Insight ▼ Bearish

Monitor for Form 4 filings to confirm whether the proposed sale is executed. The sustained selling by an officer over several weeks may signal a lack of confidence ahead of upcoming catalysts or earnings. Compare to any upcoming news or data readouts.

DirectionBearish
Confidencemedium
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
ANAB ▲ +13.22% at T+60d
SHORT call ✗ call lost -13.22% · α vs SPY -9.22% · entry $50.37 → $57.03
Entry anchored
Jun 5, 12:36 PM ET
via exchange tick
T+1d
+1.97%
call -1.97% · α -1.74%
$51.36
settled 4mo ago
T+5d
+11.32%
call -11.32% · α -10.75%
$56.07
settled 4mo ago
T+20d
+23.70%
call -23.70% · α -21.84%
$62.31
settled 3mo ago
T+60d
+13.22%
call -13.22% · α -9.22%
$57.03
settled 4w ago

Price Chart

Loading chart...

Executive Summary

Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 5, 2026, indicating intent to sell 20,000 common shares valued at approximately $1.04 million. The proposed sale follows a stock option exercise and is part of a broader pattern of insider selling, with Mulroy having sold over 126,000 shares in the prior three weeks across multiple transactions. While the filing itself is an advance notice of intent, the sustained selling by an officer warrants attention.

Key Facts

  • Officer Dennis Mulroy filed Form 144 on June 5, 2026, to sell 20,000 shares valued at ~$1.04 million.
  • The proposed sale follows a stock option exercise of 20,000 shares on June 4, 2026.
  • Mulroy has sold a total of 126,422 shares between May 15 and June 3, 2026, with proceeds exceeding $7.2 million.
  • The filing is an advance notice of intent; the sale may or may not be executed.
  • No other insider activity or cross-filings are present in the provided context.

Financial Impact

Proposed sale of 20,000 shares at ~$1.04M; cumulative insider selling by this officer over past three weeks exceeds $7.2M.

insider selling volumedilution

Risk Factors

  • Insider selling may indicate bearish sentiment or personal liquidity needs; sustained selling by an officer is a negative signal.
  • The stock may face selling pressure if the proposed sale is executed and additional insider sales continue.
  • No positive catalysts or cross-filings are present to offset the insider selling pattern.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005679
Document: 0001950047-26-005679-index.html0001950047-26-005679
Document: 0001950047-26-005679.txt0001950047-26-005679
24 reports for ANAB
Performance horizon
71% Hit rate 12 of 17 directional calls best @ T+60▲ +41.26%Mar 3, 2026
Filters
Rows
Reports for ANAB — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
Institutional Cluster
BULLISH ★ 5/10
$56.02 $53.87▼ −3.84%▼ −2.09%$48.53 (−13.37%)
Jun 29, 2026
13w ago
144
BEARISH ★ 6/10
$67.50 $53.61▲ +20.58%▲ +19.55%$48.53 (+28.10%)
Jun 29, 2026
13w ago
DEFA14A
NEUTRAL ★ 2/10
$67.50 $53.61▼ −20.58%▼ −19.55%$48.53 (−28.10%)
Jun 26, 2026
14w ago
144
BEARISH ★ 6/10
$65.97 $54.15▲ +17.92%▲ +17.64%$48.53 (+26.44%)
Jun 22, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$59.43 $50.29▼ −15.38%▼ −16.54%$48.53 (−18.34%)
Jun 17, 2026
15w ago
144
BEARISH ★ 5/10
$57.51 $54.15▲ +5.84%▲ +6.38%$48.53 (+15.61%)
Jun 15, 2026
15w ago
144
BEARISH ★ 6/10
$57.61 $62.51▼ −8.51%▼ −8.31%$48.53 (+15.76%)
Jun 11, 2026
16w ago
144
BEARISH ★ 6/10
$56.07 $66.39▼ −18.41%▼ −16.63%$48.53 (+13.45%)
Jun 10, 2026
16w ago
144
BEARISH ★ 5/10
$54.24 $66.59▼ −22.77%▼ −20.88%$48.53 (+10.53%)
Jun 8, 2026
16w ago
144
BEARISH ★ 5/10
$51.63 $67.33▼ −30.40%▼ −28.95%$48.53 (+6.00%)
Showing 10 of 24

US Market Status

Market Closed — Opens Mon (38h 32m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access